Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

NCT05555251 is registered in ClinicalTrials.gov with BioInvent International AB as lead sponsor.

NCT NCT05555251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05555251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
Lead sponsor
BioInvent International AB
Phase
Phase 1/2
Overall status
Terminated
Start date
July 28, 2022
Completion date
February 7, 2024
Enrollment
18 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer, her2-positive gastric cancer, her2-positive metastatic breast cancer, metastatic gastric adenocarcinoma, metastatic gastroesophageal junction adenocarcinoma